OBI Pharma EBIT

The latest EBIT for 4174.TWO is $-1.6B as of June 2026. That compares with $-2.6B in the prior-year period — up 38.3% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside OBI Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4174.TWO's EBIT moved from $-2.6B to $-1.6B — a 38.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in OBI Pharma's operating scale or balance-sheet position.

Against Healthcare companies, 4174.TWO currently prints $-1.6B for EBIT, while the sector average sits near $130B. That is roughly 101.2% below the sector mean. Large gaps often invite a closer look at OBI Pharma's growth, margins, and balance sheet.

A EBIT figure of $-1.6B for 4174.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting 4174.TWO's EBIT ($-1.6B), review year-over-year change from $-2.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.